Ryan G O'Malley1, Kenneth W Mahaffey2, William F Fearon3. 1. Falk Cardiovascular Research Center, Stanford University School of Medicine, 870 Quarry Road, Stanford, CA, 94305, USA. romalley@stanford.edu. 2. Department of Medicine, Division of Cardiovascular Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, 300 Pasteur Drive, Grant S102, Stanford, CA, 94305, USA. 3. Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Room A260 MC:5319, Stanford, CA, 94305, USA.
Abstract
PURPOSE OF REVIEW: Transcatheter aortic valve replacement (TAVR) has developed into an important alternative to surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis (AS). Adjuvant antithrombotic therapies are commonly used during and after TAVR to decrease the risk of valve thrombosis and thromboembolic cerebrovascular events (CVEs) but consequently increase the risk of bleeding. This article reviews the past and current clinical data regarding adjuvant antithrombotic therapies in TAVR. RECENT FINDINGS: Cerebrovascular and bleeding events during and after TAVR are associated with substantial morbidity and mortality. Bivalirudin, a direct thrombin inhibitor, has been shown to be safe alternative to unfractionated heparin (UFH) as procedural anticoagulation during TAVR; however, sparse evidence exists to guide use of antiplatelet and anticoagulant therapies in patients after TAVR. Multiple studies comparing different antithrombotic regimens in the post-TAVR setting are currently underway. Current guidelines recommend intra-procedural anticoagulation with UFH for during TAVR and with dual antiplatelet therapy (DAPT) after TAVR. There is a need to better understand the role of adjuvant antithrombotic therapies in TAVR. The results of ongoing studies are needed to develop evidence-based guidance for the use of adjuvant antithrombotic therapies after TAVR.
PURPOSE OF REVIEW: Transcatheter aortic valve replacement (TAVR) has developed into an important alternative to surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis (AS). Adjuvant antithrombotic therapies are commonly used during and after TAVR to decrease the risk of valve thrombosis and thromboembolic cerebrovascular events (CVEs) but consequently increase the risk of bleeding. This article reviews the past and current clinical data regarding adjuvant antithrombotic therapies in TAVR. RECENT FINDINGS: Cerebrovascular and bleeding events during and after TAVR are associated with substantial morbidity and mortality. Bivalirudin, a direct thrombin inhibitor, has been shown to be safe alternative to unfractionated heparin (UFH) as procedural anticoagulation during TAVR; however, sparse evidence exists to guide use of antiplatelet and anticoagulant therapies in patients after TAVR. Multiple studies comparing different antithrombotic regimens in the post-TAVR setting are currently underway. Current guidelines recommend intra-procedural anticoagulation with UFH for during TAVR and with dual antiplatelet therapy (DAPT) after TAVR. There is a need to better understand the role of adjuvant antithrombotic therapies in TAVR. The results of ongoing studies are needed to develop evidence-based guidance for the use of adjuvant antithrombotic therapies after TAVR.
Authors: Philippe Généreux; Stuart J Head; Nicolas M Van Mieghem; Susheel Kodali; Ajay J Kirtane; Ke Xu; Craig Smith; Patrick W Serruys; A Pieter Kappetein; Martin B Leon Journal: J Am Coll Cardiol Date: 2012-04-11 Impact factor: 24.094
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Corrado Tamburino; Davide Capodanno; Angelo Ramondo; Anna Sonia Petronio; Federica Ettori; Gennaro Santoro; Silvio Klugmann; Francesco Bedogni; Francesco Maisano; Antonio Marzocchi; Arnaldo Poli; David Antoniucci; Massimo Napodano; Marco De Carlo; Claudia Fiorina; Gian Paolo Ussia Journal: Circulation Date: 2011-01-10 Impact factor: 29.690
Authors: George D Dangas; Thierry Lefèvre; Christian Kupatt; Didier Tchetche; Ulrich Schäfer; Nicolas Dumonteil; John G Webb; Antonio Colombo; Stephan Windecker; Jurriën M Ten Berg; David Hildick-Smith; Roxana Mehran; Peter Boekstegers; Axel Linke; Christophe Tron; Eric Van Belle; Anita W Asgar; Andreas Fach; Raban Jeger; Gennaro Sardella; Hans Ulrich Hink; Oliver Husser; Eberhard Grube; Efthymios N Deliargyris; Ilknur Lechthaler; Debra Bernstein; Peter Wijngaard; Prodromos Anthopoulos; Christian Hengstenberg Journal: J Am Coll Cardiol Date: 2015-10-15 Impact factor: 24.094
Authors: Wilson Y Szeto; John G Augoustides; Nimesh D Desai; Patrick Moeller; Michael L McGarvey; Elizabeth Walsh; Amr Bannan; Howard C Herrmann; Joseph E Bavaria Journal: J Card Surg Date: 2011-07 Impact factor: 1.620
Authors: Martin B Leon; Craig R Smith; Michael J Mack; Raj R Makkar; Lars G Svensson; Susheel K Kodali; Vinod H Thourani; E Murat Tuzcu; D Craig Miller; Howard C Herrmann; Darshan Doshi; David J Cohen; Augusto D Pichard; Samir Kapadia; Todd Dewey; Vasilis Babaliaros; Wilson Y Szeto; Mathew R Williams; Dean Kereiakes; Alan Zajarias; Kevin L Greason; Brian K Whisenant; Robert W Hodson; Jeffrey W Moses; Alfredo Trento; David L Brown; William F Fearon; Philippe Pibarot; Rebecca T Hahn; Wael A Jaber; William N Anderson; Maria C Alu; John G Webb Journal: N Engl J Med Date: 2016-04-02 Impact factor: 91.245